2m 2m 2m 2m 2m 2m 2m
- N/AMarket Cap
- -55.65%1-Year Change
- Drug Manufacturers - Specialty & GenericIndustry
REGENCELL (RGC)
Key Performance
More- Earnings Score: N/A
- Momentum Score: 16
- True Yield: N/A
- Financial Health Score: N/A
Latest Research & News
Class action lawsuits have been filed against LKQ Corporation, Regencell Bioscience Holdings Limited, and Globant S.A. The complaints allege that defendants made materially false and misleading statements and failed to disclose material adverse facts about their businesses. LKQ faced issues with FinishMaster losing major customers post-acquisition, Regencell was vulnerable to market manipulation, and Globant faced decreasing demand in Latin America with frozen wages.
06/22/2026, 10:53 AM • GlobeNewswire
Rosen Law Firm has announced securities class action lawsuits against FS KKR Capital Corp. (FSK), Regencell Bioscience Holdings Limited (RGC), and Microsoft (MSFT). The FSK lawsuit alleges the company made false statements regarding portfolio restructuring effectiveness, investment valuations, and distribution strategy durability. Investors with losses exceeding $100K are encouraged to join the class action before the July 6, 2026 deadline for FSK and June 23, 2026 for RGC.
06/21/2026, 10:57 PM • GlobeNewswire
Rosen Law Firm is encouraging investors with losses exceeding $100,000 in Regencell Bioscience Holdings Limited, FS KKR Capital Corp., and Microsoft to join securities class action lawsuits. The firm has set a June 23, 2026 deadline for lead plaintiff claims. The lawsuits allege that defendants made false or misleading statements regarding market manipulation vulnerabilities and regulatory risks.
06/21/2026, 10:37 PM • GlobeNewswire
Faruqi & Faruqi, LLP is reminding investors in Regencell Bioscience Holdings Limited (RGC) of the June 23, 2026 deadline to seek lead plaintiff status in a federal securities class action. The lawsuit alleges that Regencell and its executives made false and misleading statements by concealing the company's vulnerability to market manipulation and the resulting regulatory risks. The DOJ investigation was disclosed on October 31, 2025, causing RGC's share price to fall 18.56% on November 3, 2025.
06/20/2026, 8:09 PM • GlobeNewswire
Rosen Law Firm has issued multiple securities class action deadline alerts for investors. The primary case involves Sportradar Group AG (SRAD), where investors who purchased shares between November 7, 2024 and April 21, 2026 may be entitled to compensation. The lawsuit alleges that Sportradar made false statements about compliance and worked with black-market gambling operators while claiming strict regulatory adherence. The lead plaintiff deadline is July 17, 2026. Similar deadline alerts were also issued for FS KKR Capital Corp. (FSK) and Regencell Bioscience Holdings Limited (RGC).
06/18/2026, 5:44 PM • GlobeNewswire
Rosen Law Firm is reminding investors in Regencell Bioscience Holdings Limited (RGC) and AeroVironment, Inc. (AVAV) of upcoming lead plaintiff deadlines in securities class action lawsuits. The lawsuits allege that defendants made false or misleading statements regarding market manipulation vulnerabilities, regulatory risks, and financial exposure during their respective class periods.
06/18/2026, 1:42 PM • GlobeNewswire
Pomerantz LLP filed a class action lawsuit against Regencell Bioscience Holdings Limited for alleged securities fraud. The lawsuit covers investors who purchased shares between October 28, 2024 and October 31, 2025. Regencell's stock experienced extreme volatility, surging to $78 per share in June 2025 before collapsing, with no corresponding business fundamentals. The company received a DOJ subpoena investigating trading in its ordinary shares, which triggered an 18.56% stock price decline upon disclosure.
06/16/2026, 3:44 PM • GlobeNewswire
Rosen Law Firm announces securities class action lawsuits against Regencell Bioscience Holdings Limited, Sportradar Group AG, and TruBridge, Inc. Investors with losses exceeding $100,000 are encouraged to join the litigation before the June 23, 2026 deadline. The lawsuits allege false and misleading statements regarding market manipulation, regulatory risks, and undisclosed material information.
06/15/2026, 8:32 PM • GlobeNewswire
A class action lawsuit has been filed against Regencell Bioscience Holdings Ltd. (NASDAQ: RGC) alleging that company defendants made materially false and misleading statements regarding the company's business operations and compliance policies. The lawsuit claims Regencell was vulnerable to market manipulation and failed to disclose associated risks to investors. The class period covers purchases between October 28, 2024 and October 31, 2025, with a lead plaintiff deadline of June 23, 2026.
06/14/2026, 12:00 PM • GlobeNewswire
A federal securities class action has been filed against Regencell Bioscience Holdings Limited (NASDAQ: RGC) alleging that the company and its executives made false and misleading statements by concealing vulnerability to market manipulation and regulatory risks. The DOJ launched an investigation into trading in RGC's ordinary shares, disclosed on October 31, 2025, causing the stock to fall 18.56%. Investors who purchased RGC securities between October 28, 2024 and October 31, 2025 may be eligible to participate in the lawsuit, with a June 23, 2026 deadline to seek lead plaintiff appointment.
06/13/2026, 8:20 AM • GlobeNewswire
A class action lawsuit has been filed against Regencell Bioscience Holdings Ltd. (NASDAQ: RGC) alleging that company defendants made materially false and misleading statements regarding the company's business operations and compliance policies. The complaint specifically alleges that Regencell was vulnerable to market manipulation and failed to disclose associated risks to investors. The class period covers purchases between October 28, 2024 and October 31, 2025, with a lead plaintiff deadline of June 23, 2026.
06/10/2026, 12:00 PM • GlobeNewswire
Rosen Law Firm has filed class action lawsuits against Verra Mobility Corporation, Sportradar Group AG, and Regencell Bioscience Holdings Limited on behalf of investors who purchased securities during specified periods. The lawsuits allege that defendants made materially false and misleading statements to investors. Verra Mobility is accused of concealing adverse facts about its relationship with Avis Budget Group and downplaying risks of contract replacement.
06/09/2026, 2:38 PM • GlobeNewswire
Rosen Law Firm announces a securities class action lawsuit against Regencell Bioscience Holdings Limited for allegedly making false and misleading statements regarding market manipulation vulnerabilities and regulatory risks during the period between October 28, 2024 and October 31, 2025. Investors have until June 23, 2026 to serve as lead plaintiff.
06/06/2026, 8:10 AM • GlobeNewswire
Rosen Law Firm is encouraging investors with losses exceeding $100K in Regencell Bioscience Holdings Limited, Calix, Inc., and Wise Group plc to join securities class action lawsuits. The firm is seeking lead plaintiffs before the June 23, 2026 deadline. Regencell is accused of making false statements regarding market manipulation vulnerability and regulatory risks.
06/03/2026, 8:45 PM • GlobeNewswire
Regencell Bioscience Holdings Limited faces a securities fraud class action lawsuit after disclosing a DOJ investigation into trading of its ordinary shares on October 31, 2025. The company revealed it received a subpoena and faces potential fines, penalties, and significant legal costs. Following the announcement, Regencell's stock price fell 18.56%. The lawsuit alleges defendants made materially false statements and failed to disclose the company's vulnerability to market manipulation and regulatory risks. The deadline to file a lead plaintiff motion is June 23, 2026.
06/03/2026, 12:34 PM • GlobeNewswire
Peers
Statistics
MoreInformation as of 06/22/2026
Company Profile
Regencell Bioscience Holdings Limited operates as a Traditional Chinese medicine (TCM) bioscience company in Hong Kong. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily for attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.
Key Executives
- Wai Hong Chung
- Michelle Chan
- Antonia Assang
- Yat-Pui Au
- Yat-Gai Au
Current Ownership Distribution
- Insiders459.0M (92.82%)
- Mutual Funds29.3M (5.93%)
- Other3.2M (0.66%)
- Institutions2.9M (0.59%)